Glutide for Ending Methamphetamine

Part of paid clinical trials in San Francisco, California.

Sponsor
San Francisco Department of Public Health
Study ID
NCT07204249
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Methamphetamine-dependence

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD. The second phase will be a phase IIb randomized-controlled trial to determine the efficacy of Wegovy in treating MeUD. This trial will be similar to the pilot with randomization to Wegovy or placebo and blinding of group assignment. The trial will enroll 162 participants across two sites.

Key Dates

Start date
Feb 26, 2026
Status verified
Jun 2026
Primary completion
Feb 15, 2030
Completion
Feb 15, 2030

Study Design

Enrollment
162 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide (Wegovy)
  • Placebo Comparator: Placebo

Primary Outcome Measure

Ratio of eligible to enrolled participants [ Time Frame: 14 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Center on Substance Use and HealthSan FranciscoCalifornia94102
Xochitl Luna Marti, MPH
[email protected]
6282176235

Find similar trials in San Francisco, CA

By research site
Center on Substance Use and Health· San Francisco, CA

Related Studies